Literature DB >> 8254192

Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc gamma RII/CD32) that inhibits the binding of immune complexes to Fc gamma R+ cells.

A Astier1, H de la Salle, C de la Salle, T Bieber, M E Esposito-Farese, M Freund, J P Cazenave, W H Fridman, J L Teillaud, D Hanau.   

Abstract

Langerhans cells (LC) express Fc gamma RII on their cell surface. In this paper, we demonstrate that these cells also release soluble Fc gamma RII (sFc gamma RII) molecules. LC express transcripts encoding a membrane-associated receptor and a transmembrane-deleted Fc gamma RIIA. The latter form was identified in LC culture supernatants using specific antibodies. CHO cells, transfected with LC-derived cDNA encoding the transmembrane-deleted Fc gamma RIIA, secrete sFc gamma RIIA that include the intracellular domain and exhibit the same backbone as the protein identified in LC supernatants. Secreted sFc gamma RIIA exhibits the same pattern of binding to human and mouse IgG subclasses as do membrane Fc gamma RII and inhibits the binding of immune complexes to Fc gamma RII+ cells. In addition, CHO cells expressing the membrane-associated Fc gamma RIIA release truncated and unstable Fc gamma RIIA molecules that lack the intracellular domain. Thus, sFc gamma RII can result from shedding of membrane molecules and/or from secretion of soluble receptors lacking the transmembrane domain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8254192

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins.

Authors:  Hicham Bouhlal; Denis Martinvalet; Jean-Luc Teillaud; Catherine Fridman; Michel D Kazatchkine; Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2014-04-01       Impact factor: 8.317

2.  Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.

Authors:  Lydie Cassard; Joël F G Cohen-Solal; Annie Galinha; Xavier Sastre-Garau; Claire Mathiot; Jérôme Galon; Thierry Dorval; Alain Bernheim; Wolf H Fridman; Catherine Sautès-Fridman
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  Specific detection of antibodies to different flaviviruses using a new immune complex ELISA.

Authors:  Herbert Schmitz; Martin Gabriel; Petra Emmerich
Journal:  Med Microbiol Immunol       Date:  2011-05-01       Impact factor: 3.402

Review 4.  Fc gamma receptors and cancer.

Authors:  Lydie Cassard; Joël Cohen-Solal; Sophie Camilleri-Broët; Emilie Fournier; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Springer Semin Immunopathol       Date:  2006-11-10

Review 5.  Cutaneous defenses against dermatophytes and yeasts.

Authors:  D K Wagner; P G Sohnle
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

6.  Soluble FcgammaRIIa inhibits rheumatoid factor binding to immune complexes.

Authors:  Bruce D Wines; Amanda Gavin; Maree S Powell; Michael Steinitz; Russell R C Buchanan; P Mark Hogarth
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

7.  Recombinant soluble Fc gamma RII inhibits immune complex precipitation.

Authors:  A L Gavin; B D Wines; M S Powell; P M Hogarth
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

8.  Channel catfish soluble FcmuR binds conserved linear epitopes present on Cmu3 and Cmu4.

Authors:  Deepak K Nayak; Aihua Tang; Melanie Wilson; Norman W Miller; Eva Bengtén
Journal:  Mol Immunol       Date:  2009-12-23       Impact factor: 4.407

Review 9.  The role of Fc receptors in HIV prevention and therapy.

Authors:  Austin W Boesch; Eric P Brown; Margaret E Ackerman
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

10.  Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens.

Authors:  S Amigorena; D Lankar; V Briken; L Gapin; M Viguier; C Bonnerot
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.